Catalyst Biosciences garners $30M in VC

Morgenthaler Ventures has led the second round of venture capital for South San Francisco-based Catalyst Biosciences. Catalyst gains $30 million to help its work engineering protease products. Catalyst has been expanding on the therapeutic applications of proteases through high-throughput protein engineering.

"Therapeutic proteases represent a class of molecules with the potential breadth and scope of antibodies, and with advantages including very high potency, automatic biomarker creation and rapid lead discovery," said Chris Christoffersen, general partner at Morgenthaler Ventures. "Catalyst is a very promising company that we believe has the opportunity to define and lead this new field, and to develop products to meet medical needs unmet by current approaches."

- Read this release for more

ALSO: Inflabloc Pharmaceuticals of Salt Lake City has raised $6 million in its third round. The money will be used to fund a Phase II trial of its lead candidate. Release

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.